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Stlmllrlary 
Recombinant granulocyte/macrophage-colony-stimulating factor (rGM-CSF),  prepared from 
Chinese hamster ovary (CHO) cells and Escherichia coli, was administered to 35 patients with 
the borderline and polar lepromatous forms of leprosy by the intradermal and subcutaneous routes 
at doses of 7.5-45.0/zg/d for 10 d. With each of these doses and routes, increases in the number 
of circulating eosinophils were noted.  After the  intradermal injection,  the local  skin  sites 
demonstrated zones of roughening and micronod~arity that appeared within 2  A.  AS h and persisted 
for more than 6 d. Reinjection of sites led to enhanced areas of epidermal reaction. GM-CSF 
prepared from CHO  cells was a more potent inducer of this effect.  GM-CSF  given by the 
subcutaneous route, at higher doses, failed to initiate these changes.  At the microscopic level, 
the epidermis became thickened (+ 75 %) with increased numbers and layers of enlarged keratinocyteg 
These contained increased numbers of ribosomes and prominent nucleoli, and were imbedded 
in a looser meshwork of the zona Pellucida. The modified keratinocytes remained MHC class 
II antigen negative throughout the course of the response. A major change in the dermis was 
the progressive accumulation of CDI+, Birbeck granule-positive cells. These Langerhans were 
recognizable at 48 h after intradermal injection and reached maximum numbers by 4 d. During 
this period the number of epidermal Langerhans cells remained relatively constant. No increment 
in dermal Langerhans cells occurred when GLM-CSF was injected by the subcutaneous route. 
No appreciable increase in the numbers of T cells and monocytes was noted, and granulocytes 
and eosinophils were largely present within the dermal microvasculature.  4-mm punch biopsies 
taken from injected sites and adjacent controls were compared in terms of the rapidity of wound 
healing. 22 of 26 sites demonstrated more rapid filling and hemostasis, whereas four were equivalent 
to controls. We conclude that rGM-CSF, when introduced into the skin, leads to enhanced 
keratinocyte growth, the selective recruitment of Langerhans cells into the dermis, and enhanced 
wound healing of the prepared site. There was no evidence of an enhanced ceU-mediated response 
to Mycobacterium leprae, and bacillary  numbers remained unchanged. 
O 
ur previous studies have dissected some of the cellular 
and molecular events associated with cell-mediated im- 
munity in humans (1). These have focussed largely on delayed- 
type cutaneous responses, after the introduction of antigens 
or recombinant lymphokines (2).  One  of the prominent 
changes noted in the epidermis, overlying an antigen-generated 
response,  was an increase in epidermal thickness as well as 
keratinocyte size and numbers (3). The effector molecules as- 
sociated with this event were then explored using cultured 
keratinocytes (4). These studies indicated that II.-3 and GM- 
CSF possessed stimulatory effects on keratinocyte growth in 
vitro. GM-CSF also has other effects on cutaneous cells and 
is a major factor in potentiating the APC capacity of Lange- 
rhans cells and inducing their cell division (5, 6). In addi- 
tion, GM-CSF is a well-known stimulant of myeloid cells 
in the marrow and a modest activator of circulating mono- 
cytes (7). These studies prompted us to examine the effects 
of rGM-CSF when introduced into the skin of patients with 
severe leprosy. We now report on the novel effects of GM- 
CSF on keratinocytes and Langerhans cells in situ. 
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Patient Population.  35 leprosy patients, 7 females and 28 males, 
(13-55 yr old, 29 with polar lepromatous leprosy, and 6 with bor- 
derline lepromatous leprosy (8), were selected for GM-CSF adminis- 
tration. Patients were seen at the Clinical Branch of the Leonard 
Wood Memorial Center for Leprosy Research (Cebu City, Philip- 
pines). Patients in reaction were excluded from the study. Written 
consent was obtained from all patients. 
Patients had been treated from <1 to 21 mo with multidrug 
therapy with rifampin (600 mg/d) clofazimine (300 mg/mo and 
50 mg/d), and dapsone (100 mg/d). All chemotherapy was con- 
tinued during the study. Six sites (two ear lobes, two on the arms, 
and two lesions) were evaluated by slit smear for bacterial index 
(B.I.) 1 (9,  10) determinations at the start of the study and 21 d 
(20 patients) or 11 d (15 patients) after the first injection. The B.I. 
of patients tested ranged from 2.0 to 5.8 at the start of the study 
(mean  _+  SD at the start, 4.5  _+  0.85). 
Human  GM-CSE  Two preparations of recombinant human 
(rhu)GM-CSF were tested (Sandoz Pharma Ltd./Schering-Plough 
Ltd., Basel, Switzerland). The first was rhuGM-CSF protein pro- 
duced in CHO cells (glycoprotein) (GMC 89-107) (batch y 026 
0188).  Vials contained 0.150 mg of lyophilized protein as calcu- 
lated by amino acid analysis, or the corresponding 0.216-0217 mg 
of glycoprotein. Vials were reconstituted with 2 ml of preservative- 
free sterile water,  to give a stock solution of 75/~g/ml (isotonic, 
pli 6.7-6.8) with a specific activity of 8  x  l& chronic myelocytic 
leukemia (CML) U/mg protein. The second was rhuGM-CSF pro- 
tein produced in Escherichia coli (CSF 39-300)  (batch U028 0689) 
with  a  specific  activity  of 2  x  10  s  U/mg  acute  myelocytic 
leukemia (AML). Vials contained 0.150 mg of lyophilized protein 
were reconstituted in 0.75 ml as above to give a stock solution of 
200/~g/ml.  Reconstituted GM-CSF was  used within  2  h.  In- 
tradermal injections were given in 100-/~1 volume while subcuta- 
neous injections were given in a volume of 200 #1. 
Experimental  Design.  Collaborative arrangements were made 
with Sandoz Pharma Ltd./Schering-Plough Ltd. (Basel, Switzer- 
land) to supply rhuGM-CSF. The material used for the first clin- 
ical trial was the recombinant protein prepared from ClIO cells 
whereas the E. coli product was used in the second trial. Both clin- 
ical trials were carried out in conjunction with physicians and in- 
vestigators working in The Leonard Wood Memorial Hospital 
(Cebu City, Philippines),  under the direction of Dr. Gerald Walsh. 
In the first trial carried out in April 1990, intradermal injections 
of either 7.5/~g (10 patients) or 15.0 #g (10 patients) of the CHO 
product were administered daily for 10 d to a total of 20 patients. 
A second trial in March 1991 used the E. coli material at a dose 
of 45/~g given subcutaneously for 10 d to 15 patients. During the 
course of this systemic trial, intradermal injections of 10 and 20 
#g were also used. Nine patients received 10-/~g intradermal injec- 
tions on day 1 of the study and all 15 patients received two 20-#g 
intradermal injections into the same site on day 6 and 7 of the study. 
All injections were given into the skin of the back of the patients. 
Before, during, and after the administration of GM-CSF,  blood 
samples were collected for the analysis of circulating cells and rou- 
tine blood chemistries. Injected sites were evaluated for macroscopic 
changes  and  sampled  by 4-mm  punch biopsies  24-144  h  after 
cytokine administration,  prepared for immunocytochemistry, trans- 
mission electron microscopy,  and histopathology. The biopsy site 
was  scored for wound healing. 
Histopathology.  A part of each biopsy specimen  was fixed in 
1 Abbreviation used in this paper: B.I., bacterial index. 
neutral buffered 10% formalin overnight, embedded in paraffin, 
sectioned, and stained with hematoxylin and eosin for histological 
diagnosis  and acid-fast  staining of enumeration of Mycobacterium 
leprae . 
Immunocytochemistry.  Biopsy specimens were fixed in PBS con- 
taining 3% paraformaldehyde,  75 mM lysine, and 10 taM'sodium 
metaperiodate (11), and were processed as described (12). Frozen 
sections were stained with mouse mAbs as described (12) to iden- 
tify cell types and phenotypes. 
mAbs.  Mouse mAbs were used for the identification of specific 
cell types. Antibodies Leu-4, Leu-2a, and Leu-3a (CD3, CD4, and 
CD8 anti-T cells) (13, 14) and Leu-M5 (CDllc, anti-monocyte/mac- 
rophage) (15) were obtained from Becton Dickinson and Co. (Moun- 
tain View, CA). Antibody OKT6 (CD1,  anti-Langerhans cells) 
(16) was obtained from Ortho Pharmaceutical Corp. (Raritan, NJ) 
and antibody 9.3F10  (anti-MHC class II antigen) was produced 
in this laboratory (17). 
Electron Microsco1~.  A part of  each biopsy was processed for trans- 
mission  EM studies.  Biopsies were fixed in 2.5% glutaraldehyde 
in 0.1 M cacodylate buffer with 0.1 M sucrose, pH 7.4, for 16 h 
at 4~  postfixed in 2% OsO4 for 1 h at 4~  stained  in block 
for 1 h with uranyl acetate in 70% ethanol, dehydrated in incre- 
ments with ethanol, and embedded in epon blocks. Sections were 
stained with lead citrate and examined with a transmission elec- 
tron microscope (JEM  100CX; Jeol USA,  Peabody, MA). 
PBMC Phenotyping.  Cells were analyzed by flow cytometry. 
The buffer used throughout consisted of PBS containing 2% FCS, 
0.1%  NaN3.  PE-conjugated  mAbs  reactive  with  CD3,  CD4, 
CD8, CD56, and CD26 (NKH1) CDllc (monocytes), CD1 (I_anger- 
hans cells), 3'/~ T cells, and CD20 (B cells) were obtained from 
Coulter Immunology (Hialeah, FL). Ceils were stained at 4~  for 
I h. After incubation, the cells were centrifuged, the supernatant 
removed, and 1 ml of PBS with 0.4% paraformaldehyde was added. 
The cells were stored at 4~  until analyzed by flow cytometry 
(Ortho Diagnostic Systems, Inc.).  At least 2,000 ceils were ana- 
lyzed in each preparation, and the percentage of positively stained 
cells was calculated. 
Determination of Epidermal Thickness.  Epidermal thickness was 
evaluated  by direct examination of hematoxylin-stained sections 
using a computer-based image digitizing system (Southern Micro 
Instruments, Inc., Atlanta, GA). The distance from the epidermal- 
dermal junction to the outer surface of the epidermis was mea- 
sured at equal intervals along the length of the sections.  At least 
25 measurements were made per section. Results were expressed 
as the ratio of mean thickness of the GM-CSF-injected site to the 
mean thickness  of the control site for each patient. 
Evaluation  of Langerhans  Cell  Numbers  in  the  Epidermis  and 
Dermis.  Sections were evaluated for specific cell staining with a 
Nikon Microphot-FX light microscope.  The numbers of CD1 + 
ceUs of the epidermis and the dermis were evaluated  by direct 
counting of the stained cell bodies (with nuclei) per  x40 micro- 
scopic field. The total area of epidermis and upper dermis was ex- 
amined on each section, CD1 + ceils counted, and the mean and 
standard deviation of the mean calculated.  At least four different 
sections, with 10 adjacent  x40 microscopic fields from every bi- 
opsy, were counted. 
Cytokine Determinations.  Plasma samples were collected before 
and after GM-CSF injection and stored at - 700C until used. GM- 
CSF and TNF-c~ concentrations were determined by spedfic ELISA 
(Endogen, Boston, MA). ELISAs were performed exactly as specified 
by the manufacturers. The limits of detection were 4-6 pg/ml. 
PCR-assisted RNA Amplification.  Total KNA preparation and 
cDNA were prepared as described (18). Lymphokine-speciflc primers 
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as well as ~-actin  (3'), were prepared and provided by S. Ehlers 
as described (19). 
Wound Healing.  Biopsy sites were evaluated daily by three in- 
dependent investigators, and the extent of  healing (drying, rounding 
of the wound edge, formation of granulation  tissue, and keratino- 
cyte growth) was evaluated. 
Results 
Clinical and Laboratory Results.  The administration of GM- 
CSF from mammalian or prokaryotic cell origin was not as- 
sociated with systemic symptoms in any of the 35 patients 
injected, except for a slight elevation in fever (a maximum 
of 39~  in seven patients. No alterations in blood chemis- 
tries or urinalysis were noted during and after the trial. The 
levels of circulating  WBC are presented in Table  1 and 2. 
After the intradermal administration of 7.5 or 15 #g of CHO 
GM-CSF to patients  (10 per group),  a small increment  in 
the total WBC count was noted. About half the increment 
was due to a threefold increase in the number of eosinophils 
(Table 2) and the rest was accounted for by enhanced number 
(~20% increase) of neutrophils. The numbers of eosinophils 
returned to preinjection levels by 21 d while those of neutro- 
phils remained sightly elevated. No differences were observed 
between the patients injected with  7.5 or  15/~g of CHO 
GM-CSF (Table 2). After the subcutaneous administration 
of 45/zg of E. coli GM-CSF to 15 patients, a smaller incre- 
ment in total WBC counts was noted, the majority of which 
was also accounted for by the increase in eosinophils.  The 
response of eosinophils to the intradermal and subcutaneous 
injection of GM-CSF is seen in Table 2.  In each case there 
was a 2-2.5-fold increase in the percentage of eosinophils in 
the absence of other significant  changes. 
Phenotypic analysis of PBMC with mAbs and FACS  |  anal- 
ysis showed no differences in the distribution  of cell types 
before and immediately after the administration of GM-CSF. 
ELISAs of serum GM-CSF and TNF-ol were uniformly nega- 
tive during  the experiment.  Finally,  PCR amplification  of 
PBMC mRNAs failed to show the induction of GM-CSF 
message and revealed no significant changes in messages for 
II.-1, II.,6,  or II.-8. 
Table  1.  Influence of rGM-CSF on  Levels of Circulating Leukocytes 
Total no. of leukocytes per mm  3 of blood 
Day 0  Day 11  Day 11-0  Day 21  Day 21-0 
A. WBC*  9,577' 
Neutrophils  5,966 
Lymphocytes/monocytes  2,978 
Eosinophils  589 
B.  WBC  11,720 
Neutrophils  7,700 
Lymphocytes/monocytes  2,930 
Eosinophils  809 
12,550  2,973  11,292  1,715 
7,128  1,162  7,413  1,447 
3,287  309  3,274  296 
1,995  1,406  575  -  14 
12,650  930  NT  NT 
7,754  54  NT  NT 
2,972  42  NT  NT 
1,632  823  NT  NT 
A, 7.5 or 15/zg recombinant CHO GM-CSF given 
daffy for 10 d. 
*.  =  20. 
* Means for all patients. 
S.  -  15. 
intradermally daffy for 10 d; or B, 45/~g recombinant E. coli GM-CSF given subcutaneously 
Table  2.  Influence of rGM-CSF on the Levels of Circulating Eosinophils 
Type of cytokine  Dose  Day 1 
Eosinophils as percent  of total  cells 
Day 11  Day 21 
A. CHO GM-CSF 
B. E. coli GM-CSF 
7.5 /zg i.d.*/d for 10 d 
15.0/~g i.d.*/d for 10 d 
45/zg s.c.*/d  for 10 d 
5.4 
6.7 
6.9 
13.8 
17.1 
12.9 
6.4 
5.3 
N.T. 
*.  g  10. 
~.  =  15. 
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Figure 1.  The local cutaneous response to intradermal GM-CSF injec- 
tion. The area (in mm  2) of modified epidermis in response to cytokine 
injection is shown for CHO GM CSF (left) (20 patients) and E. col GM- 
CSF (right) (15 patients). An early (24-h) response to a single 7.5-#g (O) 
and 15-/zg (A) CHO GM-CSF injection  peaked at 3 d and then subsided 
slowly. Keinjection of the site at 2 d (7.5 #g) and 3 d (15 #g) led to a 
consistent increase in the area of epidermis modified by the cytokine (filled 
symbols).  The first 20-#g intradermal  dose of E. cell GM-CSF ([[]) did 
not induce epidermal changes. Keinjection of the site (20 #g; filled syrabols) 
induced a local response that peaked 2 d later and then subsided slowly. 
Results are expressed as the mean area of response for all patients injected 
+  1SD. 
The Local Cutaneous Response to Intradermal Injection of rGM- 
CSF: Macroscopic Changes.  The intradermal injection of GM- 
CSF at doses of 7.5-20.0 #g/0.1 ml of diluent was followed 
by a consistent series of events, the extent and kinetics of 
which depended upon the type of the GM-CSF and the dose 
used. In all cases injection sites exhibited slight erythema and 
no significant  swelling or induration. In this sense the re- 
sponse differed markedly from the results with the intradermal 
injection of both IFN-~/and II.-2 (12, 20). Within 24 h, the 
surface of the skin of the responsive site showed roughening 
in a circular  zone up to 200 mm in diameter.  Within the 
next 24 h, examination of the area with a hand lens illus- 
trated the presence of many sites of micro-papillation con- 
tained within the roughened area and not associated with 
hair follicles. At 6 d this zone was scaly, as the keratinized 
layers were desquamated, leaving normal appearing skin. 
The areas of the epidermal response are demonstrated in 
Fig. 1, which compares the responses to rGM-CSF obtained 
from CHO cells and E. cot. It appears that on a weight basis, 
the CHO preparation (Fig. 1, left) is more potent and leads 
to a prompter (24-h) modification of the epidermis. The rein- 
jection of the site at 48 h (7.5 ~g) or 72 h (15/zg) after the 
first injection led to a consistent increase in the area of the 
responsive site with accentuation of the changes noted above. 
With the E. cot material little response occurred at 24 h 
with 10/~g (not shown) or 20/xg (Fig.  1, right), but upon 
reinjection of the 20-/~g sites, the typical cutaneous modifica- 
tions noted with the CHO-derived GM-CSF ensued. It was 
of interest that little or no epidermal change occurred when 
45/.r  of the E. coli GM-CSF was injected subcutaneously 
for a 10-d period. In only 4 of 170 sites examined was there 
a slight roughening of the overlying epidermis after subcuta- 
neous injection. 
We conclude that rGM-CSF has the ability of modifying 
the epidermis only when introduced in close proximity to 
this compartment. 
Microscopic Changes in the Epidermis.  Striking changes were 
noted in the epidermis of responsive sites when biopsies were 
examined histologically.  Within 24 h after CHO GM-CSF 
injection, enlargement of keratinocytes was apparent and the 
thickness of the epidermis was increased (Fig. 2). Quantita- 
tive analysis of the biopsies indicated that the epidermis had 
increased in thickness by a mean of 75% by 24 h  and re- 
mained thickened for -120 h (Fig.  3). These effects were 
not observed as clearly after E. cot GM-CSF injection into 
the skin. The fine structure of the epidermis will be discussed 
in a later section. 
Histopatholog~ and Bacillary Indices of Skin Biopsies and Slit 
Smears.  Biopsies obtained from control and injected skin 
sites during the course of the intradermal and subcutaneous 
administration of rGM-CSFs  were  used  to  evaluate  the 
histopathology and B.I. of the skin in these patients. Con- 
trol specimens  showed the usual sparse mononudear cell 
infiltrate of lepromatous leprosy, the majority of cells being 
macrophages with varying numbers of acid-fast bacilli (21). 
The epidermis was thin and the fetes were often shallow with 
only one to two layers of rounded, basal cells. Only a small 
amount of additional cellular infiltrate was noted during the 
course of the GM-CSF injections (Fig. 2). This consisted of 
scattered eosinophils and neutrophils and small accumulations 
of perivascular mononudear cells; in some patients these sites 
resembled the lesions of erythema nodosum leprosum without 
the vascular changes. Little else was noted in the dermis. The 
B.I.s of the patients evaluated before and after completion 
of a 10-d course of cutaneous injections of GM-CSF are shown 
in Table 3. No significant changes in the bacterial load were 
noted during this period in contrast to results obtained with 
PPD antigen, rlFN-% and rib2 (22-24). We conclude that 
locally administered GM-CSF fails to modify the mononudear 
phagocyte population of the dermis and the number of in- 
tracelular leprosy bacilli. 
Iramunocytocheraistry of the Cutaneous Site.  Immunohisto- 
logical staining of the dermal and epidermal cellular compo- 
nents are illustrated in Fig. 4. The basal, lepromatous infiltrate 
Table 3.  B.I. in Response to GM-CSF 
B.I.* 
Type of cytokine  No. of patients  Pre  Post 
CHO GM-CSF  20 
E. cot GM-CSF  15 
4.47  _+  1.06  4.43  _+  1.16 
4.54  _+  0.69  4.30  +_  0.83 
* Mean B.I.  _+  1 SD of the mean. 
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CSF on the histological appearance 
of the skin. Light micrographs  of 
sections of biopsies obtained  from 
two  representative  patients  are 
shown. A comparison ofa preincu- 
bation control site (A and C) to a 
24-h  postcytokine  administration 
site (B and D), a 96-h postcytokine 
(E),  and  an  11-d control  (F)  are 
shown for patient  no. 5. A prein- 
jection control site (G and/), 24-h 
post-  (H and .]),  and 48-h  post- 
cytokine  (K),  and an 11-d control 
(L) are shown for patient  no. 8. A 
thickening of the epidermis (arrow- 
heads) is observed already by 24 h 
(D and.J).  No systemic enhanced 
thickness is observed (F and L com- 
pared with  C  and I, respectively) 
after subcutaneous injection.  GM- 
CSF injection did not significantly 
enhance the dermal infiltration  by 
leukocytes (small  arrows). A, B, G, 
and H,  x25; C-F and I-L,  x200 
(H+E staining). 
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Effect of CHO GM-CSF on epidermal thickness. The thick- 
ness of the epidermis was evaluated for all 20 patients  before (0 d),  1-5 d 
after cytokine injection, and in control site obtained from uninjected sites 
at the end of the study (11 d postinjection). These sites enabled us to evaluate 
possible systemic effects at sites removed from cytokine  administration. 
The mean  •  1 SD of all preinjection  sites (0 d) was 53  •  9 ~m. Results 
are expressed as mean percent increase in thickness relative to preinjection 
controls  +_  I  SD. 
was MHC class II positive in both control and injected sites, 
and consisted of parasitized  macrophages and some CD3 + 
T cells (not shown). The major changes in the dermis were 
the accumulation of CD1 + Langerhans cells (Fig. 4 F). Ini- 
tially,  at 24  h  after  a tingle injection of CHO  GM-CSF, 
a few cells were scattered  randomly in the upper portion 
of the dermis. With the passage of time, and peaking at 
,'~72-96  h,  aggregates of CD1 + cells were observed in a 
dearly perivascular  location. Similar results were observed 
with E. coli GM-CSF although the numbers of dermal cells 
were lower (Fig.  5).  After a second injection of GM-CSF 
into the same site, the response was increased and the total 
number of cells accumulating in the dermis was higher. Quan- 
titative analysis of this dermal population demonstrates a 
350-700%  increase  in the number of CD1 + cells in the 
dermis in response to the local injection of E. coli-derived 
GM-CSF.  As in the case of the epidermal thickening, the 
CHO preparation appeared more potent on a weight basis 
(not shown). 
As mentioned, the epidermal keratinocytes remain MHC 
class II antigen negative throughout this series of events (Fig. 
4). This is in dear distinction to the induction of keratino- 
cyte class II antigen after the keratinocyte growth subsequent 
to the intradermal administration of antigen, IFN-% and IL-2 
(12, 20,  25).  In addition, the number of epidermal CD1 + 
Langerhans cells remains relatively constant throughout the 
post-GM-CSF injection period. Although a minor decrement 
is noted in epidermal Langerhans cell numbers (Fig. 5), this 
cannot account for the numbers accumulating in the dermis 
and suggests a vascular origin for the dermal cells. 
Electron  Microsco~  of  the Cutaneous  Sites.  Transmission elec- 
tron micrographs of the dermal and epidermal populations are 
illustrated in Figs. 6 and 7. No striking alterations were noted 
in the extent or composition of the underlying lepromatous 
infiltrate and organisms continued to be found in muhibacil- 
lary vacuoles in macrophages. Both neutrophils and eosinophils 
were apparent throughout thin sections of GM-CSF-injected 
sites. Although some were present in the tissues, the majority 
were within what appeared to be dilated elements of the micro- 
vasculature  located in the upper dermis (Fig. 6, A  and B). 
Endothelial cells of these vessels were not appreciably altered 
in contrast to the effects of II~2 (24). 
The novel dermal elements were typical Langerhans cells 
that conformed to the distribution of CD1 + cells described 
by immunocytochemistry. These cells were elongated with 
a  typical  chromatin pattern  and  contained within  their 
cytoplasm paddle shaped, Birbeck granules (Fig. 6, C-F). The 
number and distribution of cytoplasmic organelles  of the 
dermal cells was identical to that observed in the Langerhans 
cells of the epidermis. 
The keratinocyte population of GM-CSF-injected sites was 
markedly altered (Fig. 7). Many layers of more spherical cells 
were visible that contained within them increased numbers 
of free ribosomes. Although tight junctional zones were clearly 
present (Fig. 7 F), it was obvious that the keratinocytes were 
more loosely associated and demonstrated prominent inter- 
cellular spaces (Fig.  7, B, D, and F). This was in contrast 
to the tightly coupled keratinocytes of the adjacent control 
sites (Fig. 7, A, C, and E). Mitotic figures were not noted 
in the specimens examined at either the light or transmission 
EM level. Nudeoli were prominent in the larger nuclei of 
the GM-CSF-exposed keratinocyte. 
Samples obtained from patients who had received 45-/~g 
subcutaneous injections orE. coli  GM-CSF, but no intradermal 
cytokine, failed to show any of the previous findings. This 
indicates the necessity of introducing GM-CSF into the local 
environment to obtain both the enhancement in Langerhans 
cell numbers and in keratinocyte growth promotion. 
The Enhanced Wound  Healing of GM-CSF-injected  Punch Bi- 
opsy Sites.  After the excision of skin by punch biopsies, the 
healing site was evaluated daily. For the majority of the study 
simultaneous biopsies were obtained from GM-CSF-injected 
sites that exhibited the gross changes noted in Fig. I and from 
adjacent, "normal" uninjected skin. During the course of our 
initial studies with CHO GM-CSF it was noted that the bi- 
opsy rites obtained from cytokine-prepared sites healed more 
rapidly than controls. More careful quantitation of this event 
was carried out with the E. coli  product. The appearance and 
the rate of healing of these sites was evaluated on a daily basis 
in 26 pairs of biopsies  from 15 patients. 
The results of this analysis are shown in Fig. 8. Sites in- 
jected with E. coli GM-CSF were biopsied 24-96 h after the 
intradermal injection. Within 24 h of the biopsy, the GM- 
CSF-injected  site was dry, lacked bleeding points, and was 
covered by a whitish opaque film. The control site was oozing 
blood which continued to stain the overlying dressings. Both 
sites had initially been apposed with a butterfly bandage. 
1722  Effects of Recombinant GM-CSF on Lepromatous  Leprosy Patients Figure 4.  Effect of CHO GM-CSF on keratinocyte phenotype and Langerhans cell distribution. Light microscopy micrographs of biopsies sectioned 
and stained for MHC class II antigen (A, C, and E) and CD1  antigen (B, D,  and F) expression  on cells of the epidermis (arrows) and the dermis. 
MHC class II antigen was not expressed on keratinocytes  before cytokine injection (A), nor was it induced on keratinocytes  by GM-CSF injection 
at any time from 24 h (C) to 5 d. Class II antigen was not expressed on control sites at any time up to 11 d (E) after cytokine injections. The infiltrating 
cells of the dermal lepromatous lesions were MHC class II antigen positive throughout. This infiltrate was not enhanced by GM-CSF injection. CD1 
was expressed on Langerhans  cells of the epidermis before (B) as well as 24 h (D) and 72 h (F) after cytokine injection. In addition, CD1 + cells (LC) 
were observed  in the dermis in perivascular  dumps (F) after GM-CSF injection. A, C,  and E,  x150;  B, D, and F,  x250 (patient no.  5). 
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Figure S.  Effect  of GM-CSF on CD1 + Langerhans cell distribution. 
A single 10-~g (.4) or two 20-~g (B) injections orE. coil GM-CSF given 
intradermally  did not  reduce  the numbers of CD1 +  epidermal  cells 
significantly  (I) relative  to control  sites  (O) (9)" However,  dose-~-~t 
accumulation ofCD1 + cells  in the dermis in response to GM-CSF (A), 
as compared with control sites (A), was noted. Results are expressed as 
mean CD1 + cells observed per  ￿  microscopic field. 
At 48 and 72 h the control sites continued to ooze. The 
cutaneous defect had vertical sides with sharp edges. In con- 
trast, the GM-CSF-injected site became progressively  shal- 
lower as epidermal components closed the lesion. 
The enhanced process of healing was clearly evident in 22 
of the 26 biopsy sites evaluated, whereas in 4 of 26, healing 
of the control and the injected sites were equivalent.  These 
results were the composite analysis of three independent ob- 
servers. 
Diseuuion 
The present studies outline a series of novel findings that 
are the consequence of introducing rGM-CSF into the skin 
of patients with the lepromatous form of leprosy. Although 
this milieu already contains cellular elements that have been 
in the dermis for long periods of time, we see no a priori 
reason why these would influence the results as described in 
this report. Nevertheless,  studies on normal skin should be 
carried out in the future. Neither of the major effects of the 
cytokine on Langerhans cell accumulation and on keratino- 
cyte growth have been appreciated in studies after parenteral 
administration nor in transgenic mice (7, 26, 27).  In both 
situations the influence of GM-CSF on the bone marrow and 
on the products of the committed stem cells have been most 
prominent. Similarly, in our studies, following both the in- 
tradermal and subcutaneous routes, changes in the level of 
circulating leukocytes were evident. These, however, were 
restricted to an increase  in the number of circulating eosinophils 
and some neutrophils without appreciable increments in the 
number of monocytes. This may be the consequences of both 
the low dose of the agent and the short time span of the 
experiment. 
These results confirm and explain our prior observations 
on both the accumulation of CD1 + Langerhans cells in the 
dermis (28) and on the rapid growth of keratinocytes that 
overly a delayed-type cell-mediated response (3). In the latter 
case these observations were retested in an in vitro environ- 
ment. We tested the effect of selected secretory products of 
immune cells  from a  cell-mediated response on primary 
cultures of keratinocytes (4).  One of the inducing agents, 
IFN-% in fact, inhibited keratinocyte replication in vitro. 
In contrast, IL-3 and GM-CSF enhanced keratinocyte numbers 
in vitro. 
The prompt stimulation of keratinocyte growth in the in 
vivo site is, to our knowledge, quite unique in the history 
of growth factors. Epidermal growth factors, insulin, cholera 
toxin, and platdet-derived growth factor have not modified 
the growth rate of keratinocytes in situ but are widely used 
to enhance growth of cells in culture. The effect in the pa- 
tient requires a finite preparatory phase, lasts for 4-6 d, and 
allows differentiation, so that keratin synthesis, programmed 
cell death, and cell sloughing eventually ensue. As this growth 
takes place interceUularjunctions are loosened and one might 
expect that the epide~nfis becomes more permeable to exog- 
enous molecules. Another possibility is that we may be in- 
ducing the synthesis and release of keratinocyte GM-CSF or 
other molecules that extend the response. We are currently 
examining these questions by PCR analysis of keratinocyte 
mRNAs. 
We believe that the growth stimulation is related to our 
observations on more rapid wound healing. Such a scenario 
would include the rapid influx of keratinocytes into the 
wound, initially serving a hemostatic function and gradu- 
ally repairing the defect. The presence of granulocytes at the 
site might also enhance antibacterial effects. These observa- 
tions, which are based on gross examination, will be sup- 
ported in the future by more accurate evaluation carried out 
in normal skin. Even in the absence of more quantitative 
information it is nevertheless important to speculate on the 
possible roles of cutaneously administrated GM-CSF in wound 
healing. These could include the preparation of skin sites for 
subsequent surgical procedures and its topical application for 
thermal and traumatic injuries. 
The selective  accumulation of Langerhans cells in the dermis 
is of equal interest. As a result of Langerhans cell recruit- 
ment the sites contain cells capable of interacting with respon- 
sive T cells migrating through the dermis. It has already been 
shown (5, 6) that GM-CSF is a major potentiating factor 
in the antigen-presenting capacity of freshly isolated epidermal 
Langerhans cells. This report adds an additional parameter 
to GM-CSF Langerhans cells interactions. GM-CSF has not 
previously been shown to be chemotactic for these cells. The 
1724  Effects  of Recombinant GM-CSF on Lepromatous Leprosy Patients Figure 6.  The effect of GM-CSF on the cells of the dermis. Transmission electron microscopy micrographs of CHO GM-CS~injected sites. (A) 
A dilated element of the microvasculature  is observed. The lumen (La) contains a number of erythrocytes and granulocytes (PMN). The wall of the 
vessel appears normal (arrowheads). Ouly a few cells are observed in the e~travascular dermal space (x2,700).  (B) A dose-up of a granulocyte (PMN) 
within the vasculature lumen (Lu). The endothelium (EC) appears normal and tight junctiom (arrowheads) are intact (x 12,200). (C) A cellular inf~trate 
in the dermis cont~inlng a degranulated granulocyte (PMN), a Langerhans cell (LC), macrophages (Ma),  and a few lymphoid cells (x  4,500). (D) 
A dermal I.angerhans cell (LC) adjacent to a mast cell (MC). Birbeck granules are observed in the cytoplasm  of the Langerhans cell (arrows) (x12,000). 
(E and F) High magnification micrographs of dermal Langerhans cells (LC) with  multiple Birbeck granules (arrows) (x 28,000). 
1725  Kaplan  et al. Figure 7,  The effect of GM-CSF on the cells of the epidermis. Transmission electron microscopy  micrographs of CHO GM-CSF-injected (B, D, 
and F) and control (A, C, and E) sites. Controls: epidermal keratinocytes (KC) of control sites are closely  associated (arrows  in C) with limited extracei- 
lular space (0) between the cells. Tight junctions are prominent between adjacent cells in E (arrows)  (A,  x4,300; C,  xg,000; and E,  x25,000). 
GM-CSF sites: epidermal keratinocytes  (KC) of  GM-CSF-injected  sites are loosely  associated  (arrotvs  in D) with large spaces  between them (￿9  Keratino- 
cyte nuclei are large and nucleoli are prominent (arrowhea&).  Tight junctions are prominent in F (arrows).  B,  ￿  D,  x7,200; and F,  x25,000. 
Nu, nucleus, arrowheads in C and F mark the dermal epidermal junction. 
1726  Effects  of Recombinant GM-CSF on Lepromarous Leprosy Patients Figure 8.  The effect  of GM-CSF on wound healing. Biopsy sites (4 
mm) were  evaluated  for 3 d for their extent of healing. Control sites (left) 
continued to bleed for longer and the walls of the wound remained ver- 
tical for longer than the GM-CSF-injected  sites (right). Sites  were  injected 
with two 20-#g doses of//. coli GM-CSF with a 24-h interval and were 
biopsied 24-72 h after the second  cytokine  injection. By 5-6 d both types 
of wounds were relativdy well healed. 
present results suggest the induction of a selective chemoat- 
tractive stimulus. We suspect that Langerhans cell precursors 
enter the dermis from the circulation and then mature in the 
perivascular  zone in large aggregates.  Since no measurable 
number of CD1 + cells is observed in the peripheral  blood 
during GM-CSF injections, we suggest the presence of less 
mature circulating cells. We speculate that the normal produc- 
tion of GM-CSF by epidermal keratinocytes is the stimulus 
for  the  continual  emigration  of Langerhans  cells into  the 
differentiating  keratinocyte layer.  We also suspect that  the 
emigration of Langerhans cells into ddayed-type hypersensi- 
tivity sites as evoked by antigen, IFN-% and IL2 is secondary 
to the local production of GM-CSE  Finally,  the absence of 
MHC class II antigen on the GM-CSF-induced modified ker- 
atinocyte indicates the absence of  appreciable amounts of IFN-3r 
released into  this environment. 
Although GM-CSF is widely considered to both enhance 
the number and functional properties of macrophage popu- 
lations  (7), little influence on this cell series  was noted.  In 
contrast to IFN-~ and IL-2 (12,  20), no effect of GM-CSF 
was noted evoking a local emigratory  monocyte response, 
nor stimulating macrophages to destroy leprosy bacilli in these 
short-term  studies. 
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